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STa, the heat-stable enterotoxin ofEscherichia coli, stimulates membrane-bound guanylate cyclase in enterocytes, elevates cyclic GMP, and results 
in intestinal secretion of ions and fluid. Using the T84 colon carcinoma cell line as a model, Weikel et al. reported that phorbol esters enhance 
STa-stimulated cyclic GMP production by 61%140% [(1990) Infect. Immun. 58, 1402 1407]. In the present report we demonstrate that the acetylcho- 
line analog carbachol enhanced toxin-stimulated cyclic GMP accumulation i  intact T84 cells by 50-100% and that this effect was blocked by 10 
/~M atropine and 10/IM sphingosine. Pertussis toxin treatment of the T84 cells did not affect the subsequent response to carbachol. Carbachol, 
which elevates intracellular calcium in these cells, may act through protein kinase C to enhance cyclic GMP production. 
Heat-stable enterotoxin; Escherichia coli; Guanosine 3',5'-cyclic monophosphate; Phorbol ester; Carbachol; Protein kinase C; Muscarinic receptor 
1. INTRODUCTION 
Toxigenic Escherichia coli infections are the most 
common cause of traveller's diarrhea in adults as well as 
a leading cause of diarrhea in children in developing 
countries [1]. The small peptide toxin STa, the heat- 
stable toxin of E. coli, binds with high affinity to a 
receptor apparently distinct from particulate guanylate 
cyclase (GTP pyrophosphate lyase [cyclizing], EC 
4.6.1.2) and stimulates the latter enzyme [2,3]. The T84 
cell line is a human colon carcinoma cell line which 
responds to STa with a rise in cyclic GMP and to car- 
bachol with a rise in intracellular calcium; both 
secretagogues result in chloride secretion [4-7]. Weikel 
et al. recently showed that phorbol esters, which alone 
have no effect on cyclic GMP levels, enhanced STa- 
stimulated cyclic GMP levels by 1.6-2.4-fold [8]. Since 
carbachol is likely to activate protein kinase C in T84 
cells [7] we tested this cholinergic agonist for its ability 
to 'prime' T84 cells for STa-induced cyclic GMP ac- 
cumulation in a way similar to phorbols. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
T84 cells were obtained from the American Type Culture Collec- 
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Abbreviations: STa, the heat-stable enterotoxin of Escherichia coli 
(this toxin has also been referred to as STp and ST-I by some authors); 
cyclic GMP, guanosine-3',5'-cyclic monophosphate; G-protein, 
guanine nucleotide binding protein or guanine nucleotide regulatory 
protein 
tion (ATCC, Rockville, MD) at passage 50 and were grown for 25 ad- 
ditional passages as described previously [8,9]. 
2.2. Cyclic GMP accumulation i  intact cells 
To cells grown in 24-well plates additions to various wells were 
made as follows: potential inhibitors (atropine, sphingosine), when 
present, were added first; next carbachol was added to a final concen- 
tration of 100 #M; within 2-5 min of the addition of carbachol the 
toxin STa was added to a final concentration f 0.5 #M (1/~g/ml). At 
time intervals of 1-60 min after the addition of STa, cyclic GMP ac- 
cumulation was terminated by the addition of 0.5 ml of 0.2 M HC1. 
Cell protein was determined as described [9]. 
Sphingosine was prepared fresh for each use as an initial 2 mM 
stock in 55 °70 ethanol, and the final concentration in the cell wells was 
10-12.5 #M in 0.3% ethanol. Pertussis toxin [9,10] was the gift of 
Erik Hewlett, Univ. of Virginia, and was applied to the cells growing 
in standard medium at 1 /xg/ml for 16 h before beginning an experi- 
ment. This dose and length of pertussis treatment was previously 
shown to result in 99070 ADP-ribosylation of G-protein substrate in
T84 cells [9] and also is sufficient to abolish somatostatin's inhibition 
of agonist-induced cyclic AMP generation in T84 cells (data not 
shown). 
2.3. Cyclic GMP radioimmunoassay 
Cell extracts in 0.1 M HCI were acetylated, then analyzed by 
automated radioimmunoassay as previously described [8,9,11]. An- 
tibody to cyclic GMP was a gift of Joel Linden, as was ~25I-succinyl 
cyclic GMP tyrosine methyl ester prepared by the method of Patel and 
Linden [12]. 
2.4. Materials 
Purified STa prepared by the method of Dreyfus et al. [13] was a 
gift of Donald C. Robertson, Univ. of Kansas. Carbachol, atropine, 
sphingosine, 3-isobutyl-l-methylxanthine, a d other reagents were 
obtained form Sigma Chemical Co. (St. Louis, MO), and cell culture 
media and supplies were from Gibco (Grand Island, NY). 
2.5. Data analysis 
The data shown are expressed as means _+ SD, and the Student's 
t-test was used to test statistical significance. 
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Fig. 1. Effect of carbachol on STa-stimulated cyclic GMP accumula- 
tion in intact T84 cells. Cells were incubated in medium containing l 
mM of the phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine 
as described in section 2. STa alone (final concentration 0.5 #M, a 
maximal dose, a ), carbachol alone (final concentration 100 #M, • ), 
normal saline alone ( ta ) or carbachol plus STa (o) were added as in- 
dicated. When carbachol and STa were both present he carbachol 
was added 3 min before STa. This experiment is typical of 8 such ex- 
periments. In 2 other experiments cyclic GMP levels at 3-15 rain did 
not differ in cells treated with STa alone vs STa plus carbachol. 
3. RESULTS 
The time course of cyclic GMP accumulation i  in- 
tact T84 cells in response to toxin and carbachol is 
shown in Fig. 1. Carbachol alone (100 #M) did not alter 
cyclic GMP levels compared to control cells throughout 
a 45 min incubation. STa (0.5 #M) added alone produc- 
ed its expected increase in cyclic GMP, but the com- 
bination of STa plus carbachol caused an even further 
increase in cyclic GMP levels which was statistically 
significant by 20 min. In 11 separate xperiments, the 
addition of carbachol plus STa produced a mean in- 
crease in cyclic GMP of 78°-/0 over that seen with STa 
alone at the 45 min time point (range, 30-100% in- 
crease). Despite this, carbachol does not stimulate 
guanylate cyclase activity in T84 cell homogenates or
membranes (data not shown). 
T84 cells were next treated with atropine to test 
whether carbachol, a nonselective cholinergic agonist, 
was acting via muscarinic receptors in the T84 cell line. 
In 3 experiments 10 #M of the muscarinic antagonist 
atropine completely blocked the effect of 100 #M car- 
bachol (Table I, upper portion). 
Muscarinic effects on intracellular calcium concen- 
trations are believed to result from an interaction of the 
receptor via a guanine nucleotide regulatory protein (G- 
protein) with a phosphatidylinositol-specific phospho- 
lipase C [14-16]. The G-protein coupled to muscarinic 
receptors has been reported to be susceptible to per- 
tussis toxin in some systems but not others [16]. T84 
cells fully intoxicated with pertussis toxin (see section 2) 
were tested for their ability to respond to carbachol plus 
STa with an increase in cyclic GMP (Table I, lower por- 
tion). These experiments showed that carbachol's abili- 
ty to enhance STa-stimulated cyclic GMP accumulation 
was not diminished in pertussis-treated T84 cells. 
One of the best studied potential inhibitors of protein 
kinase C is sphingosine [17,18]. Since carbachol was 
hypothesized to be acting via protein kinase C the effect 
of this lipid on STa- and carbachol-stimulated cyclic 
GMP accumulation was tested. Figure 2 demonstrates 
that while 10 #M sphingosine had no effect on cyclic 
GMP accumulation i duced by STa alone (columns 3 
and 7), this concentration of sphingosine blocked the 
Table I 
Effect of atropine and pertussis toxin on carbachol-enhanced, STa-stimulated cyclic GMP accumulation i intact T84 cells 
Test agent Experiment no Ratio of cyclic GMP Ratio of cyclic GMP accum- P value 
accumulation observed ulation observed with 
with carbachol + STa test agent + carbachol + 
compared to STa alone + STa compared to 
STa alone 
Atropine (10 #M) 
Pertussis toxin (1 #g/ml x 16 h) 
l 1.40 0.96 
2 1.30 0.94 
3 1.54 0.90 
Mean 1.41 + 0.1 0.93 ± 0.03 
1 1.40 1.25 
2 1.30 1.25 
3 1.65 1.65 
4 1.30 1.42 
5 1.64 1.33 
Mean 1.46 + 0.17 1.38 ± 0.17 
0.03" 
0.34 a 
Experiments measuring cyclic GMP in intact T84 cells in response to STa, STa plus carbachol, and either atropine or pertussis toxin are combined 
in this table. Data from the 45 min time point only are shown. To allow comparisons of different experiments, cyclic GMP levels observed under 
various experimental conditions are expressed as a ratio to that observed with STa alone. 
ap value by paired, one-tailed t-test 
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enhancement i  cyclic GMP by carbachol (columns 4 
and 5). 
4. DISCUSSION 
Following the observation of Weikel et al. that phor- 
bol esters 'prime' T84 cells for STa-stimulated cyclic 
GMP accumulation [8], we investigated whether amore 
physiologic stimulus would have a similar effect. We 
chose to test the acetylcholine analog carbachol since it 
was known that T84 cells respond to carbachol with a 
rise in intracellular calcium, an intracellular messenger 
which can potentiate he activation of protein kinase C. 
Huott et al. had previously examined the cyclic GMP 
response of T84 cells to STavs STa plus carbachol for 
15 min and did not note an increase in cyclic GMP with 
the addition of carbachol [5]. Based on our data, 
however, 15 min is too early to see an effect of car- 
bachol (Fig. 1 and other experiments not shown). The 
reason for the slow onset of the carbachol effect is not 
completely clear since the calcium rise induced by car- 
bachol is rapid (within 1 min) and transient (offset 
within 5 min [7]). Phorbol ester treatment of T84 cells 
causes a rapid (within 10 min) increase in guanylate 
cyclase as assayed in broken cell preparations* while 
peak enhancement i  cyclic GMP levels requires 45-60 
min in intact cells [8]. Thus there is a lag in the ap- 
pearance of cyclic GMP changes in these whole-cell ex- 
periments done in the presence of phosphodiesterase in- 
hibitor. Another hypothesis  that carbachol treatment 
stabilizes toxin-stimulated guanylate cyclase in an active 
state, a phenomenon which has been demonstrated in 
the case of protein kinase C activation of adenylate 
cyclase from GH4CI pituitary cells [19]. 
The action of carbachol is mediated via muscarinic 
receptors as shown by the atropine xperiments (Table 
I). We did not choose to further define the muscarinic 
receptor subtype in the T84 cell, but preliminary data in 
the T84 cell** suggest that the intracellular calcium rise 
is mediated by a receptor which would be designated M3 
in recent classifications [15,16]. In other tissues other 
muscarinic subtypes have been linked to phosphoinosi- 
tide hydrolysis [20,21]. Muscarinic receptors coupled to 
inhibition of adenylate cyclase operate via the pertussis- 
sensitive G-proteins, but muscarinic receptors coupled 
to phosphoinositide hydrolysis and elevation of in- 
tracellular calcium in other animal species and tissues 
have more often been pertussis-insensitive [15]. Thus 
*Crane, J.K., Guerrant, R.L., Linden, J. and Weikel, C.S. Phorbol 
esters potentiate guanylate cyclase stimulation by the heat-stable toxin 
of Escherichia coli (STa) and increase toxin binding sites, Mol. Phar- 
macol. (submitted for publication) 
**Dharmsathaphorn, K, Beuerlein, G., Reinlib, L., Pandol, S., 
Donowitz, M. and Cohen, J. (1988) Gastroenterology 94, A98 
(Abstr.) 
E 
o 
E & 
Effect of Carbachol and Sphingosine on 
STa-stimulated Cyclic GMP Accumulation 
,,.£ 800I  ~-,~ o ] 
_1 ¢/~ o O) I 
1 I-- ml lml  I ' -o  + '~ Z / 
400 .+  
o ÷ ÷ 
300 
20o 
I00 
0 
0 
"5 
o 
1 2 3 4 5 6 7 8 
Condition 
Fig. 2. Ef fect  o f  carbachol and sphingosine on STa-stimulated cyclic 
GMP accumulation. Cyclic GMP levels were measured as described in 
section 2, 45 min after addition of 0.5/~M STa with other additions 
as indicated in the figure. Sphingosine was added approximately 20 
rain before carbachol and STa. Abbreviations: phingo, sphingosine; 
carb, 100 #M carbachol. Wells receiving 10/~M sphingosine had a 
final concentration of 0.3% ethanol and those receiving 50 #M 
sphingosine had 1.5°70 ethanol. The experiment shown is represen- 
tative of 4 such experiments. 
the lack of effect of pertussis toxin in these human in- 
testinal cells is consistent with previous reports. 
Sphingosine has been reported to be a potent in- 
hibitor of protein kinase C [17], but it is not specific 
because it also can inhibit several other protein kinases, 
including Ca 2 ÷/calmodulin-dependent kinases, myosin 
light chain kinase, and cyclic nucleotide dependent pro- 
tein kinases [18]. Thus the effect of sphingosine shown 
in Fig. 2 suggests but does not prove that the carbachol 
effect is mediated via protein kinase C. 
Elevation of cyclic GMP levels in tissues in response 
to cholinergic agonists has been known for over 20 
years [22,23], but the mechanism of signal transduction 
from receptor to cyclic nucleotide remains undefined. 
In many cell types the isoenzyme of guanylate cyclase 
responsible for cyclic GMP production in response to 
cholinergic agonists has been either undefined or solu- 
ble (cytosolic) guanylate cyclase based on its stimula- 
tion by calcium and its abundance in the tissue under 
study [24,25]. In the T84 cell and other intestinal tissues 
particulate or membrane-bound guanylate cyclase 
heavily predominates ([25,26] and J. Crane, unpublish- 
ed data) and is the form stimulated by STa. The present 
report is, to our knowledge, the first to show that car- 
bachol can enhance agonist-stimulated cyclic GMP pro- 
duction via the membrane-bound form of guanylate 
cyclase. In addition, the similarity of the effect of car- 
bachol and the effect of phorbol esters in these cells sug- 
gests a common mechanism, possibly a phosphoryla- 
tion of guanylate cyclase by protein kinase C. 
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Based on the present results showing an interaction 
between carbachol and STa on cyclic GMP levels, 
Levine et al. have investigated whether these two secre- 
tagogues also interact at the level of chloride ion secre- 
tion, measured as short-circuit current (Isc) across T84 
cell monolayers. The results confirm that carbachol and 
STa, when added simultaneously, induce a supra-addi- 
tive or synergistic increase in Isc compared to each ago- 
nist added alone***. These results may also provide an 
explanation for previous, poorly understood in vivo 
observations showing inhibition of STa-induced secre- 
tion in intestinal segments by cholinergic blockers in 
rats and cats [27]. Thus the interaction of carbachol and 
STa may have important physiologic implications, since 
the enteric nervous system and gastrointestinal hor- 
mones which raise intracellular calcium could affect 
one's susceptibility to diarrhea due to toxigenic 
Escherichia coli. 
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